| 試験進捗状況 | 主たる結果の公表済み/Main results already published |
| UMIN試験ID | UMIN000045597 |
| 受付番号 | R000051980 |
| 科学的試験名 | 試験食品摂取による有効成分の血中吸収確認試験 |
| 一般公開日(本登録希望日) | 2021/10/06 |
| 最終更新日 | 2022/02/18 (5版) |
| 基本情報/Basic information | |||
| 一般向け試験名/Public title | 試験食品摂取による有効成分の血中吸収確認試験 | Test for confirmation of absorption of a compound by ingestion of test foods | |
| 一般向け試験名略称/Acronym | 試験食品摂取による有効成分の血中吸収確認試験 | Test for confirmation of absorption of a compound by ingestion of test foods | |
| 科学的試験名/Scientific Title | 試験食品摂取による有効成分の血中吸収確認試験 | Test for confirmation of absorption of a compound by ingestion of test foods | |
| 科学的試験名略称/Scientific Title:Acronym | 試験食品摂取による有効成分の血中吸収確認試験 | Test for confirmation of absorption of a compound by ingestion of test foods | |
| 試験実施地域/Region |
|
||
| 対象疾患/Condition | ||||
| 対象疾患名/Condition | なし | none | ||
| 疾患区分1/Classification by specialty |
|
|||
| 疾患区分2/Classification by malignancy | 悪性腫瘍以外/Others | |||
| ゲノム情報の取扱い/Genomic information | いいえ/NO | |||
| 目的/Objectives | ||
| 目的1/Narrative objectives1 | 経口摂取した場合の成分の吸収性について、起原原料と食品原料との違いを確認する。 | Confirm the difference between origin raw materials and food ingredient in terms of absorption of compound when taken orally. |
| 目的2/Basic objectives2 | 薬物動態/Pharmacokinetics | |
| 目的2 -その他詳細/Basic objectives -Others | ||
| 試験の性質1/Trial characteristics_1 | ||
| 試験の性質2/Trial characteristics_2 | ||
| 試験のフェーズ/Developmental phase | ||
| 評価/Assessment | ||
| 主要アウトカム評価項目/Primary outcomes | 血漿中未変化体成分濃度 | Concentration of intact components in blood plasma |
| 副次アウトカム評価項目/Key secondary outcomes | ||
| 基本事項/Base | ||
| 試験の種類/Study type | 介入/Interventional | |
| 試験デザイン/Study design | ||
| 基本デザイン/Basic design | クロスオーバー試験/Cross-over | |
| ランダム化/Randomization | ランダム化/Randomized | |
| ランダム化の単位/Randomization unit | 個別/Individual | |
| ブラインド化/Blinding | オープンだが測定者がブラインド化されている/Open -but assessor(s) are blinded | |
| コントロール/Control | プラセボ・シャム対照/Placebo | |
| 層別化/Stratification | ||
| 動的割付/Dynamic allocation | ||
| 試験実施施設の考慮/Institution consideration | ||
| ブロック化/Blocking | ||
| 割付コードを知る方法/Concealment | ||
| 介入/Intervention | |||
| 群数/No. of arms | 2 | ||
| 介入の目的/Purpose of intervention | 治療・ケア/Treatment | ||
| 介入の種類/Type of intervention |
|
||
| 介入1/Interventions/Control_1 | 起原原料(果実可食部および種子)約250gの単回摂取 | single oral ingestion about 250g of raw material ( fruit eatable part and seed ) | |
| 介入2/Interventions/Control_2 | 起原原料から抽出・精製された食品原料を配合した食品(飲料)1250mLの単回摂取 | Single oral ingestion 1250mL of food (beverages) containing food ingredients extracted and refined from raw materials. | |
| 介入3/Interventions/Control_3 | |||
| 介入4/Interventions/Control_4 | |||
| 介入5/Interventions/Control_5 | |||
| 介入6/Interventions/Control_6 | |||
| 介入7/Interventions/Control_7 | |||
| 介入8/Interventions/Control_8 | |||
| 介入9/Interventions/Control_9 | |||
| 介入10/Interventions/Control_10 | |||
| 適格性/Eligibility | |||||
| 年齢(下限)/Age-lower limit |
|
||||
| 年齢(上限)/Age-upper limit |
|
||||
| 性別/Gender | 男女両方/Male and Female | ||||
| 選択基準/Key inclusion criteria | (1)同意取得時の年齢が20歳以上65歳未満の男女
(2)BMIが18.5kg/m^2以上30.0kg/m^2未満の者 (3)第1期試験日の1週間前までに、新型コロナウィルスワクチンの2回接種が終了している者 (4)当該試験について十分な説明を受け、内容を理解することができ、本人による文書同意が得られる者 |
(1) Men and women aged 20 to 65 years at the time of obtaining consent
(2) BMI of 18.5 kg/m^2or more but less than 30.0 kg/m^2. (3) Those who have completed two doses of the new coronavirus vaccine at least one week prior to the first test day. (4) Those who have received sufficient explanation of the test, understand the contents, and can give written consent in person. |
|||
| 除外基準/Key exclusion criteria | (1)酸味を苦手とする者
(2)現在、何らかの服薬治療をしている者 (3)第1期試験日の1週間前から第2期試験日までの間に服薬治療や各種ワクチン接種の予定がある者 (4)アルコール多飲者 (5)試験日の前日、普段通りに就寝して睡眠をとることが出来ない者 (6)血管が細い、採血しづらいと言われたことがあり、複数回の採血が困難な者 (7)月経不順、月経痛、更年期障害に関連する症状等が重いと自覚している者 (8)心臓、肝臓、腎臓、消化器等に重篤な疾患の既往歴および現病歴がある者 (9)妊娠中、授乳中、あるいは試験期間中に妊娠する意思のある者 (10)医薬品および食物にアレルギーがある者 (11)他の医薬品または健康食品の臨床試験に参加中、試験終了後4週間以内、 あるいは当該試験の参加同意後に他の臨床試験に参加する予定のある者 (12)当該試験開始前月から成分献血あるいは全血200 mL献血を行った者 (13)当該試験開始3ヶ月前から全血400 mL献血を行った男性 (14)当該試験開始4ヶ月前から全血400 mL献血を行った女性 (15)当該試験開始12ヶ月前からの採血量に、当該試験の予定総採血量を加えると1200 mLを超える男性 (16)当該試験開始12ヶ月前からの採血量に、当該試験の予定総採血量を加えると800 mLを超える女性 (17)試験責任医師または試験分担医師が本試験への参加が不適当と判断した者 |
(1) People who have difficulty with acidity
(2) Those who are currently taking any medication. (3) Those who are scheduled to take medication or receive vaccinations between one week before the first test date and the second test date. (4) Heavy drinkers of alcohol (5) Those who are unable to go to bed and sleep as usual the day before the test day (6) Those who have been told that their blood vessels are too thin or that it is difficult to draw blood more than once (7) Those who are aware that they have severe symptoms such as irregular menstruation, menstrual cramps, or symptoms related to menopausal disorders. (8) Those who have a history or current history of serious diseases of the heart, liver, kidneys, digestive organs, etc. (9) Those who are pregnant, lactating, or intend to become pregnant during the study period. (10) Those with allergies to medicines or food (11) Those who are currently participating in a clinical trial of another drug or health food, and plan to participate in another clinical trial within 4 weeks of the end of the trial, or after consenting to participate in the trial. (12) Those who have donated component blood or 200 mL whole blood since the month prior to the start of the study. (13) Men who have donated 400 mL of whole blood for 3 months prior to the start of the study. (14)Women who have donated 400 mL of whole blood for 4 months prior to the start of the study (15) Men whose total blood collection volume exceeds 1200 mL when the planned total blood collection volume for the study is added to the blood collection volume from 12 months prior to the start of the study (16)Women whose blood volume exceeds 800 mL when the total planned blood volume for the study is added to the blood volume collected 12 months prior to the start of the study. (17) Patients who are judged to be inappropriate for participation in the study by the principal investigator or sub-investigator. Translated with www.DeepL.com/Translator (free version) |
|||
| 目標参加者数/Target sample size | 10 | ||||
| 責任研究者/Research contact person | ||||||||||||||
| 責任研究者/Name of lead principal investigator |
|
|
||||||||||||
| 所属組織/Organization | 森永製菓株式会社 研究所 | R&D Institute, MORINAGA & CO., LTD. | ||||||||||||
| 所属部署/Division name | 健康科学研究センター | Health Science Research Center | ||||||||||||
| 郵便番号/Zip code | 230-8504 | |||||||||||||
| 住所/Address | 神奈川県横浜市鶴見区下末吉2-1-1 | Shimosueyoshi 2-1-1 Tsurumi-ku Yokohama-si Kanagawa-ken | ||||||||||||
| 電話/TEL | 045-571-2982 | |||||||||||||
| Email/Email | y-matsui-jd@morinaga.co.jp | |||||||||||||
| 試験問い合わせ窓口/Public contact | ||||||||||||||
| 試験問い合わせ窓口担当者/Name of contact person |
|
|
||||||||||||
| 組織名/Organization | 森永製菓株式会社 研究所 | R&D Institute, MORINAGA & CO., LTD. | ||||||||||||
| 部署名/Division name | 健康科学研究センター | Health Science Research Center | ||||||||||||
| 郵便番号/Zip code | 230-8504 | |||||||||||||
| 住所/Address | 神奈川県横浜市鶴見区下末吉2-1-1 | Shimosueyoshi 2-1-1 Tsurumi-ku Yokohama-si Kanagawa-ken | ||||||||||||
| 電話/TEL | 045-571-2982 | |||||||||||||
| 試験のホームページURL/Homepage URL | ||||||||||||||
| Email/Email | s-mori-ab@morinaga.co.jp | |||||||||||||
| 実施責任組織/Sponsor | ||
| 機関名/Institute | その他 | R&D Institute, MORINAGA & CO., LTD. |
| 機関名/Institute (機関選択不可の場合) |
森永製菓株式会社 研究所 | |
| 部署名/Department | ||
| 研究費提供組織/Funding Source | ||
| 機関名/Organization | 自己調達 | R&D Institute, MORINAGA & CO., LTD. |
| 機関名/Organization (機関選択不可の場合) |
森永製菓株式会社 研究所 | |
| 組織名/Division | ||
| 組織の区分/Category of Funding Organization | 営利企業/Profit organization | |
| 研究費拠出国/Nationality of Funding Organization | ||
| その他の関連組織/Other related organizations | ||
| 共同実施組織/Co-sponsor | ||
| その他の研究費提供組織/Name of secondary funder(s) | ||
| IRB等連絡先(公開)/IRB Contact (For public release) | ||
| 組織名/Organization | チヨダパラメディカルケアクリニック倫理審査委員会 | Institutional Review Board of Chiyoda Paramedical Care Clinic |
| 住所/Address | 東京都千代田区内神田3-3-5 山和内神田ビル2階 | 2F Chushin Building, 3-3-5 Uchikanda Chiyoda-ku, Tokyo 101-0047, Japan |
| 電話/Tel | 03-5297-5548 | |
| Email/Email | IRB@cpcc.co.jp | |
| 他機関から発行された試験ID/Secondary IDs | ||
| 他機関から発行された試験ID/Secondary IDs | いいえ/NO | |
| 試験ID1/Study ID_1 | ||
| ID発行機関1/Org. issuing International ID_1 | ||
| 試験ID2/Study ID_2 | ||
| ID発行機関2/Org. issuing International ID_2 | ||
| 治験届/IND to MHLW | ||
| 試験実施施設/Institutions | ||
| 試験実施施設名称/Institutions | ||
| その他の管理情報/Other administrative information | ||||||||
| 一般公開日(本登録希望日)/Date of disclosure of the study information |
|
|||||||
| 関連情報/Related information | ||
| プロトコル掲載URL/URL releasing protocol | ||
| 試験結果の公開状況/Publication of results | 未公表/Unpublished | |
| 結果/Result | ||
| 結果掲載URL/URL related to results and publications | ||
| 組み入れ参加者数/Number of participants that the trial has enrolled | 10 | |
| 主な結果/Results | ||
| 主な結果入力日/Results date posted | ||
| 結果掲載遅延/Results Delayed | ||
| 結果遅延理由/Results Delay Reason | ||
| 最初の試験結果の出版日/Date of the first journal publication of results | ||
| 参加者背景/Baseline Characteristics | ||
| 参加者の流れ/Participant flow | ||
| 有害事象/Adverse events | ||
| 評価項目/Outcome measures | ||
| 個別症例データ共有計画/Plan to share IPD | ||
| 個別症例データ共有計画の詳細/IPD sharing Plan description | ||
| 試験進捗状況/Progress | ||||||||
| 試験進捗状況/Recruitment status | 主たる結果の公表済み/Main results already published | |||||||
| プロトコル確定日/Date of protocol fixation |
|
|||||||
| 倫理委員会による承認日/Date of IRB |
|
|||||||
| 登録・組入れ開始(予定)日/Anticipated trial start date |
|
|||||||
| フォロー終了(予定)日/Last follow-up date |
|
|||||||
| 入力終了(予定)日/Date of closure to data entry | ||||||||
| データ固定(予定)日/Date trial data considered complete | ||||||||
| 解析終了(予定)日/Date analysis concluded | ||||||||
| その他/Other | ||
| その他関連情報/Other related information | ||
| 管理情報/Management information | ||||||||
| 登録日時/Registered date |
|
|||||||
| 最終更新日/Last modified on |
|
|||||||
| 閲覧ページへのリンク/Link to view the page | |
| URL(日本語) | https://center6.umin.ac.jp/cgi-open-bin/ctr/ctr_view.cgi?recptno=R000051980 |
| URL(英語) | https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000051980 |